Last updated: 11/07/2018 14:49:07
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.
Trial description: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Benericial effects of rosiglitazone on insulin resistance and endothelial dysfunetion in patients with Type 2 diabetes, J.-P. Albertinil, H. Chen R. Mather P. E. Valensi. Munich; Germany. 40th Annual Meeting of the European Association for the Study of Diabetes (EASD). 9/5/2004
Agrawal A, Chen H, Yan Y et al. Rosiglitazone improves postprandial glycaemia and markers of endothelial function in patients with type 2 diabetes. Diabetologia 2002; 45 (Suppl 2): Abs and poster 781 presented at EASD 2002.
Agrawal A, Chen H, Yan Y et al. Rosiglitazone improves postprandial glycemia and markers of endothelial function in patients with type 2 diabetes. Diabetes 2002; 51 (Suppl 2): Abs and poster 372-P presented at ADA 2002.
Albertini JP, Chen H, Mather R, Valensi P. Markers of endothelial dysfunction and insulin resistance. Beneficial effects of rosiglitazone. Diabetes 200453 (Suppl 2):A117 Poster 494 presented at ADA 2004
Valensi P, Albertini JP, Chen H et al. Rosiglitazone improves markers of endothelial function and postprandial glycemia in type 2 diabetic patients. Published in ENDO 2002 congress book. Abs and poster P1-61 presented at ENDO 2002.
Medical condition
Diabetes Mellitus, Type 2
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
January 2000 to February 2001
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-26-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website